Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
Maria Cosenza, Monica Civallero, Stefania Fiorcari, et al.
Cancer Biology & Therapy (2016) Vol. 17, Iss. 10, pp. 1094-1106
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
Qing Zhang, Shaobin Wang, Junhui Chen, et al.
International Journal of Medical Sciences (2019) Vol. 16, Iss. 3, pp. 424-442
Open Access | Times Cited: 78
Recent Update of HDAC Inhibitors in Lymphoma
I‐Chung Chen, Bidyadhar Sethy, Jing‐Ping Liou
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 73
The discovery and development of romidepsin for the treatment of T-cell lymphoma
Piotr Smolewski, Tadeusz Robak
Expert Opinion on Drug Discovery (2017), pp. 1-15
Closed Access | Times Cited: 70
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial
Yawen Wang, Mingzhi Zhang, Wei Song, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 5, pp. 623-629
Open Access | Times Cited: 29
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin
Nasreddine El Omari, Learn‐Han Lee, Saad Bakrim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114774-114774
Open Access | Times Cited: 18
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma
Jia Ruan, Jasmine M. Zain, Brett Alan Palmer, et al.
Blood Advances (2023) Vol. 7, Iss. 19, pp. 5771-5779
Open Access | Times Cited: 16
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
Guang Lu, Shikai Jin, Su-Wen Lin, et al.
Clinical Epigenetics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Marine peptides in lymphoma: surgery at molecular level for therapeutic understanding
Salman Ahmed, Michael Aschner, Khalaf F. Alsharif, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Alessandro Broccoli, Lisa Argnani, Pier Luigi Zinzani
Cancer Treatment Reviews (2017) Vol. 60, pp. 120-129
Closed Access | Times Cited: 43
Regulatory non-coding somatic mutations as drivers of neuroblastoma
Annalaura Montella, Matilde Tirelli, Vito Alessandro Lasorsa, et al.
British Journal of Cancer (2025)
Open Access
Clinical Efficacy and Mechanistic Insights of FDA-Approved HDAC Inhibitors in the Treatment of Lymphoma
Nasreddine El Omari, Saad Bakrim, Hamza Elhrech, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107057-107057
Open Access
Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma
José R. Cortés, Christina C. Patrone, S. Aidan Quinn, et al.
Journal of Investigative Dermatology (2021) Vol. 141, Iss. 12, pp. 2908-2920.e7
Open Access | Times Cited: 21
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
Helen Ma, Ardalan Davarifar, Jennifer E. Amengual
Current Hematologic Malignancy Reports (2018) Vol. 13, Iss. 1, pp. 13-24
Closed Access | Times Cited: 25
LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis
Xiaoxuan Yu, Mengyuan Zhu, Jiarong Wang, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 2, pp. 290-300
Open Access | Times Cited: 16
New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination
Helen Ma, Owen A. O’Connor, Enrica Marchi
Expert Review of Hematology (2019) Vol. 12, Iss. 3, pp. 137-146
Closed Access | Times Cited: 17
Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78
Kazuyasu Fujii, Masashi Idogawa, Norihiro Suzuki, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11258-11258
Open Access | Times Cited: 12
ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma
Mengzhou Cao, Pan Lai, Xiangjun Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Combination Effect of Notch1 and PI3K / AKT / mTOR Signaling Pathways Inhibitors on T-ALL Cell Lines
Halimeh Khoshamooz, Saeid Kaviani, Amir Atashi, et al.
International Journal of Hematology-Oncology and Stem Cell Research (2020)
Open Access | Times Cited: 9
Transfection of STAT3 overexpression plasmid mediated through recombinant lentivirus promotes differentiation of bone marrow mesenchymal stem cells into neural cells in fetal rats with spina bifida aperta
Mingyu Jiang, Jiale Feng, Rong Fu, et al.
Aging (2021) Vol. 13, Iss. 17, pp. 21778-21790
Open Access | Times Cited: 9
Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma
Shaoxuan Hu, Dongmei Zou, Daobin Zhou, et al.
Medicine (2020) Vol. 99, Iss. 43, pp. e22788-e22788
Open Access | Times Cited: 6
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma
Nozomi Jimura, Kazuyasu Fujii, Zhiwei Qiao, et al.
Journal of Dermatological Science (2021) Vol. 101, Iss. 3, pp. 194-201
Closed Access | Times Cited: 4
Valproic Acid inhibits proliferation and promotes apoptosis of peripheral T cell lymphoma cells via the miRNA-3196/KCNK3 signaling axis
Zhiqiang Peng, Hanzhi Dong, Jianping Xiong
Research Square (Research Square) (2024)
Closed Access
A Yale Dermatology Perspective on Cutaneous T-Cell Lymphoma: Historical Reflection to Emerging Therapies
Madisen A. Swallow, Richard L. Edelson, Michael Girardi
Clinics in Dermatology (2024)
Closed Access
Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial
Jin‐Hua Liang, Li Wang, Xiaodong Wang, et al.
Chinese Medical Journal (2023) Vol. 137, Iss. 13, pp. 1576-1582
Open Access | Times Cited: 1
Valproic Acid Inhibits Peripheral T Cell Lymphoma Cells Behaviors via Restraining PI3K/AKT Pathway
Zhiqiang Peng, Jianping Xiong, Hanzhi Dong
Evidence-based Complementary and Alternative Medicine (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top